143 related articles for article (PubMed ID: 36106543)
21. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
22. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Iizuka Y; Takase-Minegishi K; Hirahara L; Kirino Y; Soejima Y; Namkoong HO; Horita N; Yoshimi R; Takeuchi M; Takeno M; Mizuki N; Nakajima H
Mod Rheumatol; 2022 Oct; 32(6):1153-1162. PubMed ID: 34752620
[TBL] [Abstract][Full Text] [Related]
23. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
[TBL] [Abstract][Full Text] [Related]
24. A novel combination treatment with apremilast and tumor necrosis factor inhibitor for a patient with refractory intestinal Behcet's disease.
Fukui S; Kawaai S; Tamaki H; Fukuda K; Okada M
Scand J Rheumatol; 2022 Jan; 51(1):81-82. PubMed ID: 34232114
[No Abstract] [Full Text] [Related]
25. [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
Fourmond S; Gutierrez B; Gourin MP; Delaumenie S; Ly KH
Rev Med Interne; 2022 May; 43(5):312-315. PubMed ID: 35219509
[TBL] [Abstract][Full Text] [Related]
26. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
Verboom DM; van der Houwen TB; Kappen JH; van Daele PLA; Dik WA; Schreurs MWJ; van Hagen PM; van Laar JAM
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):43-47. PubMed ID: 30873952
[TBL] [Abstract][Full Text] [Related]
28. Neutrophilic eccrine hidradenitis as a clue to the diagnosis of Behçet's disease: Case report with excellent response to adalimumab.
Baeza-Hernández G; Rubio-Aguilera RF; Horcajada-Reales C; Khedaoui R; Romero-Maté A
Australas J Dermatol; 2024 May; 65(3):e66-e68. PubMed ID: 38212933
[No Abstract] [Full Text] [Related]
29. The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up.
Braun-Moscovici Y; Tavor Y; Markovits D; Toledano K; Rozin A; Nahir MA; Balbir-Gurman A
Isr Med Assoc J; 2020 May; 22(5):289-293. PubMed ID: 32378820
[TBL] [Abstract][Full Text] [Related]
30. Pseudotumoral presentation of neuro-Behçet's disease in a patient receiving apremilast: A precipitating agent?
Lim M; Archambeaud A; Ferreira-Maldent N; Cottier JP; Samimi M
Ann Dermatol Venereol; 2024 Mar; 151(1):103251. PubMed ID: 38417200
[No Abstract] [Full Text] [Related]
31. Novel approaches to Behçet's disease.
Sakane T; Takeno M
Expert Opin Investig Drugs; 2000 Sep; 9(9):1993-2005. PubMed ID: 11060788
[TBL] [Abstract][Full Text] [Related]
32. Mycobacterium bovis infection under apremilast in Behçet's syndrome.
Vieira M; Vautier M; Charlotte F; Saadoun D
Rheumatology (Oxford); 2021 Sep; 60(9):e301-e303. PubMed ID: 33668049
[No Abstract] [Full Text] [Related]
33. Successful treatment of adalimumab for older Behçet's disease complicated with pulmonary artery thrombosis: A case report.
Yoshida S; Kimura Y
Int J Rheum Dis; 2020 Jun; 23(6):837-839. PubMed ID: 32406191
[No Abstract] [Full Text] [Related]
34. Apremilast in dermatology: A review of literature.
Nassim D; Alajmi A; Jfri A; Pehr K
Dermatol Ther; 2020 Nov; 33(6):e14261. PubMed ID: 32876993
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.
Li Y; Han Z; Wang X; Mo Z; Zhang W; Li A; Liu S
BMC Gastroenterol; 2013 Dec; 13():167. PubMed ID: 24321021
[TBL] [Abstract][Full Text] [Related]
36. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
37. [Behçet's Syndrome].
Xenitidis T; Henes JC
Laryngorhinootologie; 2020 Jun; 99(6):377-390. PubMed ID: 32557459
[TBL] [Abstract][Full Text] [Related]
38. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G; Mahr A; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35798511
[TBL] [Abstract][Full Text] [Related]
39. [Behçet's disease].
Decaux G; Nève P
Rev Med Brux; 1991 Dec; 12(10):407-11. PubMed ID: 1767148
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of Behçet's disease with lenalidomide.
Green J; Upjohn E; McCormack C; Zeldis J; Prince HM
Br J Dermatol; 2008 Jan; 158(1):197-8. PubMed ID: 17986298
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
